Navigation Links
Simvastatin Leads Pfizer's Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
Date:5/13/2008

Results from the ENHANCE Trial Impacting Physician Prescribing Patterns,

According to a New Report from Decision Resources

WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that simvastatin (Merck's Zocor, generics) leads Pfizer's Lipitor in second-line patient share -- 22.9 percent versus 14.7 percent. Most patients progressing to simvastatin do so after switching from Lipitor. Surveyed primary care physicians and cardiologists cite simvastatin's better reimbursement and formulary status as the primary reason to prescribe simvastatin instead of Lipitor. Nevertheless, despite the availability of generic statins, more than 75 percent of Lipitor's prescriptions stem from first-line therapy.

The report entitled Treatment Algorithms in Dyslipidemia also finds that, prior to the release of the ENHANCE trial results, Merck/Schering-Plough's Vytorin and AstraZeneca's Crestor also gained significant second-line patient shares-13.1 percent and 10.9 percent, respectively. These gains reflect physicians' efforts to boost efficacy in patients whose initial low-density lipoprotein (LDL) lowering treatment had been less than optimal; surveyed physicians perceive these agents to offer the best LDL-reducing ability. However, 47 percent of surveyed primary care physicians and 49 percent of surveyed cardiologists have changed their prescribing of Merck/Schering- Plough's Zetia and Vytorin because of data from the ENHANCE trial, which showed that the addition of Zetia to simvastatin treatment did not significantly change carotid artery thickness. The majority of surveyed physicians now prescribe Vytorin and Zetia in fewer new patients, with a smaller percentage of physicians switching patients off of these drugs.

"Cardiologists we surveyed expect to decrease their first- and second-line prescriptions for Vytorin between 2008 and 2010, and to increase their third- line use of the drug in the same time period." said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, fewer surveyed primary care physicians anticipate lower use of Vytorin in first- and second-line therapy over the next two years."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field.

-- Qualitative diagnosis/referral/treatment algorithm for the United

States.

-- Drug usage by lines of therapy (1st, 2nd, 3rd line).

-- Discussion of key freeform combinations by lines of therapy.

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line).

-- Progression of therapy from key 1st line products.

-- Pathway to key therapies from previous therapies.

-- Qualitative analysis of two-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources (http://www.DecisionResources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
2. Nursing professor leads the way for telepsychiatry by nurses to treat postpartum depression
3. Prisoner HIV program leads to continuum of medical care after release
4. Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter
5. Minimally invasive pancreas surgery leads to fewer complications, study finds
6. UQ leads the way on complementary medicine research
7. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
8. When positive thinking leads to financial irresponsibility like compulsive gambling
9. Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
10. Eli Manning Leads March for Babies in Manhattan
11. MRI before surgery leads to better-adapted treatment for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology: